These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 21984976)

  • 41. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
    Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
    Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PI3K/PTEN/AKT Genetic Mouse Models of Endometrial Carcinoma.
    Joshi A; Ellenson LH
    Adv Exp Med Biol; 2017; 943():261-273. PubMed ID: 27910071
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
    Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
    Berg A; Hoivik EA; Mjøs S; Holst F; Werner HM; Tangen IL; Taylor-Weiner A; Gibson WJ; Kusonmano K; Wik E; Trovik J; Halle MK; Øyan AM; Kalland KH; Cherniack AD; Beroukhim R; Stefansson I; Mills GB; Krakstad C; Salvesen HB
    Oncotarget; 2015 Jan; 6(2):1327-39. PubMed ID: 25415225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
    Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R
    PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
    Dunn S; Eberlein C; Yu J; Gris-Oliver A; Ong SH; Yelland U; Cureton N; Staniszewska A; McEwen R; Fox M; Pilling J; Hopcroft P; Coker EA; Jaaks P; Garnett MJ; Isherwood B; Serra V; Davies BR; Barry ST; Lynch JT; Yusa K
    Oncogene; 2022 Nov; 41(46):5046-5060. PubMed ID: 36241868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
    Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
    Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of genetic alterations on mTOR-targeted cancer therapy.
    Sun SY
    Chin J Cancer; 2013 May; 32(5):270-4. PubMed ID: 23489586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
    Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X
    Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long Noncoding RNA HOTAIR Promotes Endometrial Carcinoma Cell Proliferation by Binding to PTEN via the Activating Phosphatidylinositol 3-Kinase/Akt Signaling Pathway.
    Zhang XH; Hu P; Xie YQ; Kang YJ; Li M
    Mol Cell Biol; 2019 Dec; 39(23):. PubMed ID: 31527078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
    Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
    Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
    Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
    Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Franklin RA; Montalto G; Cervello M; Libra M; Candido S; Malaponte G; Mazzarino MC; Fagone P; Nicoletti F; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Chiarini F; Evangelisti C; Cocco L; Martelli AM
    Oncotarget; 2012 Oct; 3(10):1068-111. PubMed ID: 23085539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
    St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
    Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly.
    Negishi Y; Miya F; Hattori A; Johmura Y; Nakagawa M; Ando N; Hori I; Togawa T; Aoyama K; Ohashi K; Fukumura S; Mizuno S; Umemura A; Kishimoto Y; Okamoto N; Kato M; Tsunoda T; Yamasaki M; Kanemura Y; Kosaki K; Nakanishi M; Saitoh S
    BMC Med Genet; 2017 Jan; 18(1):4. PubMed ID: 28086757
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
    Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
    Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
    Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
    Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.